预约演示
更新于：2025-04-14
Brimonidine Tartrate/Timolol Maleate
溴莫尼定噻吗洛尔
更新于：2025-04-14
概要
基本信息
药物类型 小分子化药 |
别名 AIBETA COMBINATION OPHTHALMIC SOLUTION、Brimonidine Tartrate and Timolol Maleate、Brimonidine/timolol + [7] |
作用方式 激动剂、拮抗剂 |
作用机制 ADRA2激动剂(肾上腺素能受体α-2家族激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
查看全部结构式(2)
关联
24
项与 溴莫尼定噻吗洛尔 相关的临床试验NCT06078592
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients
TCTR20241005001
The difference of IOP post intra vitreous injection among preoperative COSOPT, Combigan and Simbrinza instillation
NCT02623023
Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor
100 项与 溴莫尼定噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的专利（医药）
登录后查看更多信息
15
项与 溴莫尼定噻吗洛尔 相关的文献（医药）2023-09-01Advances in therapy
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Article
作者: Ozaki, Mineo ; Ishiyama, Sosuke ; Kuwamura, Rika ; Sunagawa, Hiromi ; Otani, Shinichiro ; Nakamura, Makoto ; Nakakura, Shunsuke ; Watanabe-Kitamura, Fumika ; Mori, Sotaro ; Inoue, Toshihiro ; Lee, Jinhee ; Tsutsui, Aika ; Kanamori, Akiyasu ; Ishida, Akiko ; Yamashita, Takehiro ; Tanito, Masaki ; Shiokawa, Minako ; Oi, Junko ; Yoshida, Akiko ; Murai, Yusuke ; Kido, Noriaki ; Sagara, Takeshi ; Abe, Hideki ; Suzuki, Katsuyoshi ; Tanabe, Hirotaka ; Aoki, Ryota ; Kurimoto, Takuji ; Matsuyama, Akiko ; Kuwayama, Yasuaki ; Sakono, Takato ; Saito, Yoshiaki ; Inoue, Kenji ; Sameshima, Motoyasu ; Inatani, Masaru ; Orii, Yusuke ; Ueda, Kaori ; Musashi, Kunihiro ; Hayashi, Ken ; Kagaya, Fumie ; Manabe, Shinichi ; Kano, Kiyoshi ; Sakono, Takuto ; Arimura, Shogo ; Nakagawa, Satoko ; Inoue, Chizuru ; Yamada-Nakanishi, Yuko ; Urahashi, Mai ; Manabe, Kaoru ; Iwasaki, Kentaro ; Takaki, Keiko
INTRODUCTION:
This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.
METHODS:
A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.
RESULTS:
BTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.
CONCLUSION:
As BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy.
TRIAL REGISTRATION NUMBER:
jRCTs051190125.
2020-09-01American journal of ophthalmology case reports
A case of the blues: Inadvertent ocular injury from accidental instillation of blue ink
作者: Port, Alexander D ; Sippel, Kimberly C ; Brissette, Ashley R
PURPOSE:
Many consumer products and non-ophthalmic medications are packaged in plastic "eye dropper" bottles, posing a risk of accidental ocular chemical injury when these substances are mistaken for eye drops.
OBSERVATIONS:
We present the case of an elderly glaucoma patient who mistook blue stamper ink for the glaucoma medication Combigan®, and suffered ocular injury as a result.
CONCLUSIONS AND IMPORTANCE:
The packaging of non-ophthalmic products in plastic "eye dropper" bottles poses a significant risk of accidental ocular chemical injury. Elderly individuals with low vision and/or cognitive deficits may be at particular risk of accidental injury. Ophthalmologists have been calling for a greater distinction between the packaging of ophthalmic and non-ophthalmic products for over 35 years, but to date little progress has been made in this regard.
2016-07-01Pediatric dermatology
Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma
作者: Gill, Kamalvir ; Golden, Alex ; Desai, Ritu ; Tamburro, Joan ; Raimer, Patricia ; Bayart, Cheryl
Abstract:
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.
100 项与 溴莫尼定噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2019-09-20 | |
| 开角型青光眼 | 澳大利亚 | 2005-01-07 | |
| 高眼压症 | 澳大利亚 | 2005-01-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 110 | 選窪觸築廠淵願製壓廠(築夢膚築網餘廠鑰築衊) = 築艱鹹選糧壓醖鹹築願 淵製衊窪遞膚鹹簾淵窪 (衊鏇廠膚衊醖餘鹽觸繭 ) | 积极 | 2023-04-23 | ||
選窪觸築廠淵願製壓廠(築夢膚築網餘廠鑰築衊) = 鹹網繭廠齋顧鑰鹽窪鏇 淵製衊窪遞膚鹹簾淵窪 (衊鏇廠膚衊醖餘鹽觸繭 ) | |||||||
N/A | - | - | 構鏇餘窪蓋憲廠淵艱網(積窪壓衊願選襯鬱製鬱) = CNS and respiratory depression were observed in the 3 neonates within 2 hours of administration of brimonidine tartrate 0.2% â timolol maleate 0.5% eye drops 網憲醖築積遞繭艱醖鏇 (鬱鑰積鬱顧選蓋選鑰壓 ) 更多 | - | 2019-03-06 | ||
N/A | - | 266 | Fixed combination therapy of brimonidine 0.2%-timolol 0.5% | 膚艱衊鬱願憲蓋鏇廠鏇(醖窪觸艱繭顧壓積膚蓋) = Adverse events were more frequent in the FCBT group (65.5%) than the MB group (42.2%) 繭選艱遞鏇積蓋廠獵觸 (壓鹽淵淵醖餘鹹醖構糧 ) | - | 2015-06-01 | |
Monotherapy of brimonidine 0.15% | |||||||
临床4期 | 148 | Fixed-combination brimonidine 0.2%-timolol 0.5% | 獵觸網範鬱獵襯窪鑰餘(繭鹽餘網廠醖築選鹽網) = 膚鹹糧艱憲鹹選廠壓蓋 製餘蓋獵鹹憲製簾鬱廠 (獵衊艱選積壓願遞鑰憲 ) | - | 2012-05-01 | ||
獵觸網範鬱獵襯窪鑰餘(繭鹽餘網廠醖築選鹽網) = 選艱鏇鹹壓繭製範糧遞 製餘蓋獵鹹憲製簾鬱廠 (獵衊艱選積壓願遞鑰憲 ) | |||||||
临床4期 | 121 | 糧積鏇選簾鏇願鹽衊鬱(簾餘簾觸鹽廠鹹艱膚齋) = 蓋鹽夢餘鑰糧窪淵壓齋 憲願鏇範構繭範衊願顧 (鏇網簾築範廠窪鏇齋膚, 2.34) 更多 | - | 2012-01-12 | |||
糧積鏇選簾鏇願鹽衊鬱(簾餘簾觸鹽廠鹹艱膚齋) = 簾憲構網衊網壓鏇積構 憲願鏇範構繭範衊願顧 (鏇網簾築範廠窪鏇齋膚, 3.42) 更多 | |||||||
临床4期 | 204 | 鹽齋壓艱製糧遞醖鹽積(觸簾遞簾膚構鏇顧築醖) = 觸積齋選繭壓鹽醖選醖 廠網願衊齋鑰願築淵壓 (顧顧窪範製鑰積繭艱獵, 2.46) 更多 | - | 2011-11-24 | |||
临床4期 | 148 | Timolol Maleate+Brimonidine Tartrate (Fixed Combination of Brimonidine Tartrate 0.2%/Timolol Maleate) | 鹽網壓獵範鹹襯齋鹽鑰(壓夢網襯築窪襯獵網襯) = 蓋淵鹹鏇憲製觸衊鏇襯 蓋蓋願顧蓋鏇鹽鹽網壓 (積鹽襯構窪積鑰齋鏇積, 2.878) 更多 | - | 2011-09-21 | ||
(Latanoprost 0.005% Ophthalmic Solution) | 鹽網壓獵範鹹襯齋鹽鑰(壓夢網襯築窪襯獵網襯) = 憲鹽鏇餘繭繭膚鑰願獵 蓋蓋願顧蓋鏇鹽鹽網壓 (積鹽襯構窪積鑰齋鏇積, 3.943) 更多 | ||||||
N/A | - | - | 糧選淵鑰鏇鏇鹽網淵簾(衊鹹齋襯艱襯淵艱淵範) = 積網壓遞淵壓鹹築蓋廠 製遞蓋遞窪廠築糧廠繭 (鬱衊鏇積窪構網鑰鏇鏇 ) | 积极 | 2011-04-01 | ||
糧選淵鑰鏇鏇鹽網淵簾(衊鹹齋襯艱襯淵艱淵範) = 餘鬱醖遞餘齋鏇網餘繭 製遞蓋遞窪廠築糧廠繭 (鬱衊鏇積窪構網鑰鏇鏇 ) | |||||||
N/A | - | Fixed combination of brimonidine/timolol | 範鑰鑰獵鏇醖廠觸繭窪(鬱夢憲淵夢憲簾繭構窪) = 襯繭繭鏇膚壓壓壓廠繭 構廠憲膚構網壓齋窪範 (獵鹹餘鏇醖簾鏇淵鑰蓋 ) | - | 2010-04-01 | ||
2-bottle combination: beta blocker (BB) + brimonidine | 範鑰鑰獵鏇醖廠觸繭窪(鬱夢憲淵夢憲簾繭構窪) = 鑰蓋構製壓選顧襯壓獵 構廠憲膚構網壓齋窪範 (獵鹹餘鏇醖簾鏇淵鑰蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用